Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 230 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Hormone Receptor Positive Breast Cancer Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer, Hormone Receptor Positive
Interventions
Palbociclib, Tamoxifen, Fulvestrant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Brain Metastases, HR+ Metastatic Breast Cancer
Interventions
Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 6:19 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Hormone Receptor-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Hormone Receptor-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Positron Emission Tomography, Treatment Planning, Treatment Regimen
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Fulvestrant
Drug
Lead sponsor
Nancy Chan, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
218
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 6:19 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
Interventions
Almac HER-Seq Assay
Diagnostic Test
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Exemestane, Metformin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
DiviTum® TKa assay, Study Care Plans
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Interventions
68Ga-R10602 injection
Drug
Lead sponsor
Radionetics Oncology
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
ribociclib (LEE011), Exemestane, Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced May 21, 2026, 6:19 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin, Trastuzumab deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
33
States / cities
Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
XL102, Fulvestrant, Abiraterone, Prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Interventions
RLY-2608, Capivasertib, Fulvestrant
Drug
Lead sponsor
Relay Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
51
States / cities
Gilbert, Arizona • Beverly Hills, California • Duarte, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced May 21, 2026, 6:19 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Hormone-receptor Positive Breast Cancer
Interventions
exemestane and pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced May 21, 2026, 6:19 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Prolonged Nightly Fasting, Exercise
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
BEZ235, BKM 120, Letrozole, BKM120
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, F-18 16 Alpha-Fluoroestradiol, Hormone Therapy, Positron Emission Tomography, Biopsy Procedure, Biospecimen Collection, Abemaciclib
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced May 21, 2026, 6:19 PM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Abemaciclib, Nonsteroidal Aromatase Inhibitor (NSAI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
70
States / cities
Daphne, Alabama • Tempe, Arizona • Fountain Valley, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced May 21, 2026, 6:19 PM EDT